While much of the world’s attention was on the evolving covid-19 regulations and COP-26 winding down last week, members of our health practice participated in the World Anti-Microbial Resistance (AMR) Congress in Washington, DC. AMR, commonly referred to as the “silent tsunami”, is one of the biggest health security risks the world faces. As our supply of effective antibiotics dwindles, new resistance mechanisms are emerging and spreading globally, threatening our ability to treat common infectious diseases.
The World AMR Congress brought together global leaders in medicine, innovators in technologies and treatments, patient advocates and academics, to tackle the challenges and opportunities we face in this space. As a conference chair, Amanda Stucke, Economist Impact senior manager and Americas regional lead opened day two of the congress with remarks on what makes AMR so unique:
“it requires new ways of innovating and collaborating across traditionally siloed sectors of human and animal health, agriculture and climate. It provides an opportunity to break down barriers, both at the systems level and for individuals, promoting equity and access. Addressing AMR also means fixing problems in our systems that will impact so much more than just AMR, including how we collect data, how we put patients at the centre, prioritise our environment, and how we ensure that the right prevention, diagnostics and treatments reach the right patients, at the right time.”
Michael Dillon, Economist Impact business development lead and David Humphreys, global head of the Economist Impact Health Practice, also led discussions at the congress. They focused on addressing AMR through collaboration between public and private sectors, and raising the importance of the patient voice in R&D and policy discussions. These sessions highlighted the complexities of AMR: it is a multi-faceted problem that requires a multi-faceted solution beyond any one sector or stakeholder to outsmart it. The congress also made clear that the need to take meaningful action to address AMR is urgent, as AMR mortality is estimated to outpace deaths from all cancers in our lifetimes. These actions must include a pursuit of a strengthened antibiotic pipeline, a steadfast commitment to the One Health approach, and economic and policy action that foster an effective enabling environment for progress. Economist Impact remains committed to being a global partner in supporting these actions in the fight against AMR globally.